Login to Your Account

Pharma: Other News To Note

Friday, February 24, 2012
• Pfizer Inc., of New York, issued a statement regarding the use of Prevnar 13 (pneumococcal 13-valent conjugate vaccine [diphtheria CRM197 protein]) in adults, 50 and older. The pharma firm said it believes Prevnar 13 should be recommended for adults in that age group, given the current burden of pneumococcal disease.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription